These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7787692)

  • 1. [A mathematical analysis of the cardiac activity indices in patients with ischemic heart disease undergoing antianginal pharmacotherapy].
    Arushanian EB; Shamliian TA
    Eksp Klin Farmakol; 1995; 58(1):31-3. PubMed ID: 7787692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The chronobiological aspects of drug resistance to antianginal therapy].
    Arushanian EB; Shamliian TA
    Eksp Klin Farmakol; 1994; 57(4):33-5. PubMed ID: 7950781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of antianginal preparations on the hemodynamics and metabolism of the ischemic myocardium].
    Makolkin VI; Vakhliaev VD
    Eksp Klin Farmakol; 1996; 59(4):18-20. PubMed ID: 9026181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of the new cardioprotective agent thiotriazoline in the therapy of ischemic heart disease in older patients].
    Dunaev VV; Kraĭdashenko OV; Berezin AE
    Eksp Klin Farmakol; 1996; 59(1):21-3. PubMed ID: 8704625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The detection of circadian fluctuations in the efficacy of pharmacotherapy in patients with ischemic heart disease using cardiointervalography].
    Arushanian EB; Shamliian TA
    Eksp Klin Farmakol; 1996; 59(2):24-6. PubMed ID: 8974558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluctuations in the stenocardia threshold of patients with ischemic heart disease].
    Kuleshova EV; Gusarov GV; Tsaĭ NV
    Ter Arkh; 1992; 64(4):23-6. PubMed ID: 1440301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of the antioxidant coenzyme Q10 as a cytoprotection variant in ischemic heart disease].
    Syrkin AL; Kogan AKh; Drinitsina SV; Kuznetsov AB; Pechorina EA; Frenkel' EE; Kuleshova NN; Golovnia LD
    Klin Med (Mosk); 1998; 76(7):24-8. PubMed ID: 9742773
    [No Abstract]   [Full Text] [Related]  

  • 8. [Psychophysiological approaches to assessing patients with painful and painless forms of ischemic heart disease].
    Lipovetskii BM; Reznikova TN; Il'ina GN; Petukhova NV; Stoianov AM
    Ter Arkh; 1995; 67(12):8-11. PubMed ID: 8820044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of a compound preparation pumpan on exercise tolerance and clinical course of ischemic heart disease].
    Krasnitskiĭ VB; Aronov DM; Zhidko NI
    Ter Arkh; 2003; 75(8):17-21. PubMed ID: 14520844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Increased myocardial resistance to ischemia in a chronic model of stenocardia].
    Pozin VM; Skuratovskaia SG; Pocheptsova GA
    Biull Eksp Biol Med; 1993 Sep; 116(9):235-8. PubMed ID: 7509646
    [No Abstract]   [Full Text] [Related]  

  • 11. [A clinico-pharmacological study of the antianginal and anti-ischemic efficacy of a new drug form of diltiazem with delayed release].
    Belousov IuB; Upnitskiĭ AA; Sokolov AV; Tishchenkova NF; Karasev AV; Egorova NA
    Ter Arkh; 1997; 69(3):61-3. PubMed ID: 9229836
    [No Abstract]   [Full Text] [Related]  

  • 12. [Consequences of circadian variability for the treatment of ischemic heart disease].
    Herren T; Urban P; Rutishauser W
    Schweiz Rundsch Med Prax; 1992 Feb; 81(7):176-82. PubMed ID: 1535952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The tourniquet test in evaluating the analgesic action of antianginal preparations].
    Zhiliaev EV; Glazunov AV
    Ter Arkh; 1993; 65(4):40-3. PubMed ID: 8059406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian variation of ischaemic events in patients with chronic stable angina: pathophysiological and therapeutical considerations.
    Chierchia SL
    Arch Mal Coeur Vaiss; 1993 Jun; 86 Spec No 3():11-4. PubMed ID: 7904444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of helium-neon laser irradiation on myocardial and thyroid functions in patients with ischemic heart disease].
    Ruzov VI; Rubanova MP; Grigor'ev MIu; Cherkunov KV
    Vopr Kurortol Fizioter Lech Fiz Kult; 1997; (5):7-9. PubMed ID: 9446315
    [No Abstract]   [Full Text] [Related]  

  • 16. [The possibilities for the pathogenetic therapy of ischemic heart disease under cardioselective loading].
    Ardashev VN; Smirnov AV; Ryndin AA; Shcherbak IuA
    Voen Med Zh; 1994 Jul; (7):29-31, 79. PubMed ID: 7810109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An amino acid metabolic complex in optimizing the cardiac hemodynamic characteristics of patients with ischemic heart disease].
    Berezin AE; Fushteĭ IM; Kraĭdashenko OV
    Lik Sprava; 1998 Dec; (8):94-6. PubMed ID: 10204359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How efficacy of antianginal drugs should be evaluated].
    Kośmicki M; Kowalik I; Sadowski Z
    Przegl Lek; 2000; 57(7-8):411-4. PubMed ID: 11109316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The optimization of the hemodynamic characteristics in patients with ischemic heart disease and circulatory failure by using a substrate-coenzyme complex].
    Vizir AD; Dunaev VV; Berezin AE; Kraĭdashenko OV
    Lik Sprava; 1997; (5):53-6. PubMed ID: 9491697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Agents for the metabolic correction of myocardial energy metabolism in treating patients with ischemic heart disease].
    Vizyr AD; Kraĭdashenko OV; Berezin OIe; Oliĭnyk OI
    Lik Sprava; 2000 Mar; (2):26-30. PubMed ID: 10862469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.